305 related articles for article (PubMed ID: 24961645)
1. Impact of minimal residual disease on outcomes after umbilical cord blood transplantation for adults with Philadelphia-positive acute lymphoblastic leukaemia: an analysis on behalf of Eurocord, Cord Blood Committee and the Acute Leukaemia working party of the European group for Blood and Marrow Transplantation.
Tucunduva L; Ruggeri A; Sanz G; Furst S; Cornelissen J; Linkesch W; Mannone L; Ribera JM; Veelken H; Yakoub-Agha I; González Valentín ME; Schots R; Arcese W; Montesinos P; Labopin M; Gluckman E; Mohty M; Rocha V
Br J Haematol; 2014 Sep; 166(5):749-57. PubMed ID: 24961645
[TBL] [Abstract][Full Text] [Related]
2. Impact of pretransplant minimal residual disease after cord blood transplantation for childhood acute lymphoblastic leukemia in remission: an Eurocord, PDWP-EBMT analysis.
Ruggeri A; Michel G; Dalle JH; Caniglia M; Locatelli F; Campos A; de Heredia CD; Mohty M; Hurtado JM; Bierings M; Bittencourt H; Mauad M; Purtill D; Cunha R; Kabbara N; Gluckman E; Labopin M; Peters C; Rocha V
Leukemia; 2012 Dec; 26(12):2455-61. PubMed ID: 22555150
[TBL] [Abstract][Full Text] [Related]
3. Improving results of autologous stem cell transplantation for Philadelphia-positive acute lymphoblastic leukaemia in the era of tyrosine kinase inhibitors: a report from the Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation.
Giebel S; Labopin M; Gorin NC; Caillot D; Leguay T; Schaap N; Michallet M; Dombret H; Mohty M
Eur J Cancer; 2014 Jan; 50(2):411-7. PubMed ID: 24210524
[TBL] [Abstract][Full Text] [Related]
4. Persistent MRD before and after allogeneic BMT predicts relapse in children with acute lymphoblastic leukaemia.
Sutton R; Shaw PJ; Venn NC; Law T; Dissanayake A; Kilo T; Haber M; Norris MD; Fraser C; Alvaro F; Revesz T; Trahair TN; Dalla-Pozza L; Marshall GM; O'Brien TA
Br J Haematol; 2015 Feb; 168(3):395-404. PubMed ID: 25312094
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for outcomes after unrelated cord blood transplantation for adults with acute lymphoblastic leukemia: a report on behalf of Eurocord and the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Tucunduva L; Ruggeri A; Sanz G; Furst S; Socié G; Michallet M; Arcese W; Milpied N; Yakoub-Agha I; Linkesch W; Cornelissen J; Mannone L; Iori AP; Ribera JM; Sanz J; Montesinos P; Purtill D; Labopin M; Gluckman E; Mohty M; Rocha V
Bone Marrow Transplant; 2014 Jul; 49(7):887-94. PubMed ID: 24986801
[TBL] [Abstract][Full Text] [Related]
6. Unrelated cord blood transplantation in adult and pediatric acute lymphoblastic leukemia: effect of minimal residual disease on relapse and survival.
Bachanova V; Burke MJ; Yohe S; Cao Q; Sandhu K; Singleton TP; Brunstein CG; Wagner JE; Verneris MR; Weisdorf DJ
Biol Blood Marrow Transplant; 2012 Jun; 18(6):963-8. PubMed ID: 22430088
[TBL] [Abstract][Full Text] [Related]
7. Factors Associated with Long-Term Risk of Relapse after Unrelated Cord Blood Transplantation in Children with Acute Lymphoblastic Leukemia in Remission.
Page KM; Labopin M; Ruggeri A; Michel G; Diaz de Heredia C; O'Brien T; Picardi A; Ayas M; Bittencourt H; Vora AJ; Troy J; Bonfim C; Volt F; Gluckman E; Bader P; Kurtzberg J; Rocha V
Biol Blood Marrow Transplant; 2017 Aug; 23(8):1350-1358. PubMed ID: 28438676
[TBL] [Abstract][Full Text] [Related]
8. Minimal residual disease before and after transplantation for childhood acute lymphoblastic leukaemia: is there any room for intervention?
Balduzzi A; Di Maio L; Silvestri D; Songia S; Bonanomi S; Rovelli A; Conter V; Biondi A; Cazzaniga G; Valsecchi MG
Br J Haematol; 2014 Feb; 164(3):396-408. PubMed ID: 24422724
[TBL] [Abstract][Full Text] [Related]
9. Analysis of risk factors for outcomes after unrelated cord blood transplantation in adults with lymphoid malignancies: a study by the Eurocord-Netcord and lymphoma working party of the European group for blood and marrow transplantation.
Rodrigues CA; Sanz G; Brunstein CG; Sanz J; Wagner JE; Renaud M; de Lima M; Cairo MS; Fürst S; Rio B; Dalley C; Carreras E; Harousseau JL; Mohty M; Taveira D; Dreger P; Sureda A; Gluckman E; Rocha V
J Clin Oncol; 2009 Jan; 27(2):256-63. PubMed ID: 19064984
[TBL] [Abstract][Full Text] [Related]
10. Measurement of minimal residual disease before and after myeloablative hematopoietic cell transplantation for acute leukemia.
Appelbaum FR
Best Pract Res Clin Haematol; 2013 Sep; 26(3):279-84. PubMed ID: 24309531
[TBL] [Abstract][Full Text] [Related]
11. The impact of pre-transplant minimal residual disease on outcome of intensified myeloablative cord blood transplant for acute myeloid leukemia in first or second complete remission.
Zheng C; Zhu X; Tang B; Zhang L; Geng L; Liu H; Sun Z
Leuk Lymphoma; 2016; 57(6):1398-405. PubMed ID: 26690538
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of Cord Blood Transplantation Using Reduced-Intensity Conditioning for Chronic Lymphocytic Leukemia: A Study on Behalf of Eurocord and Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation, and the Societé Française de Greffe de Moelle et Therapie Cellulaire.
Xavier E; Cornillon J; Ruggeri A; Chevallier P; Cornelissen JJ; Andersen NS; Maillard N; Nguyen S; Blaise D; Deconinck E; Veelken H; Milpied N; Van Gelder M; Peffault de Latour R; Gluckman E; Kröger N; Schetelig J; Rocha V
Biol Blood Marrow Transplant; 2015 Aug; 21(8):1515-23. PubMed ID: 25958294
[TBL] [Abstract][Full Text] [Related]
13. Minimal Residual Disease at First Achievement of Complete Remission Predicts Outcome in Adult Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia.
Zhang M; Fu H; Lai X; Tan Y; Zheng W; Shi J; Zhao Y; Lin M; He J; Cai Z; Luo Y; Huang H
PLoS One; 2016; 11(10):e0163599. PubMed ID: 27695097
[TBL] [Abstract][Full Text] [Related]
14. Clinical value of pre-transplant minimal residual disease in childhood lymphoblastic leukaemia: the results of the French minimal residual disease-guided protocol.
Gandemer V; Pochon C; Oger E; Dalle JH; Michel G; Schmitt C; de Berranger E; Galambrun C; Cavé H; Cayuela JM; Grardel N; Macintyre E; Margueritte G; Méchinaud F; Rorhlich P; Lutz P; Demeocq F; Schneider P; Plantaz D; Poirée M; Bordigoni P
Br J Haematol; 2014 May; 165(3):392-401. PubMed ID: 24479958
[TBL] [Abstract][Full Text] [Related]
15. Are patients with acute leukaemia, alive and well 2 years post bone marrow transplantation cured? A European survey. Acute Leukaemia Working Party of the European Group for Bone Marrow Transplantation (EBMT).
Frassoni F; Labopin M; Gluckman E; Prentice HG; Gahrton G; Mandelli F; Carella M; Herve P; Gratwohl A; Goldman J
Leukemia; 1994 Jun; 8(6):924-8. PubMed ID: 8207985
[TBL] [Abstract][Full Text] [Related]
16. Myeloablative Unrelated Cord Blood Transplantation in Adolescents and Young Adults with Acute Leukemia.
Hayashi H; Volt F; Sanz J; Petersen E; Dhedin N; Hough R; Milpied N; Angelucci E; Yakoub-Agha I; Michallet M; Michel G; Aljurf M; Kenzey C; Rocha V; Dalle JH; Bader P; Ruggeri A; Gluckman E;
Biol Blood Marrow Transplant; 2019 Dec; 25(12):2438-2446. PubMed ID: 31394275
[TBL] [Abstract][Full Text] [Related]
17. Unrelated Cord Blood Transplantation for Acute Leukemia Diagnosed in the First Year of Life: Outcomes and Risk Factor Analysis.
Ruggeri A; Volt F; Locatelli F; Michel G; Diaz de Heredia C; Abecasis M; Zecca M; Vora A; Yakouben K; O'Brien TA; Giardino S; Cornish J; Rocha V; Peters C; Bader P; Gluckman E; Dalle JH
Biol Blood Marrow Transplant; 2017 Jan; 23(1):96-102. PubMed ID: 27777140
[TBL] [Abstract][Full Text] [Related]
18. Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT.
Pavlů J; Labopin M; Niittyvuopio R; Socié G; Yakoub-Agha I; Wu D; Remenyi P; Passweg J; Beelen DW; Aljurf M; Kröger N; Labussière-Wallet H; Perić Z; Giebel S; Nagler A; Mohty M
J Hematol Oncol; 2019 Oct; 12(1):108. PubMed ID: 31647022
[TBL] [Abstract][Full Text] [Related]
19. Monitoring of minimal residual disease after allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia allows for the identification of impending relapse: results of the ALL-BFM-SCT 2003 trial.
Bader P; Kreyenberg H; von Stackelberg A; Eckert C; Salzmann-Manrique E; Meisel R; Poetschger U; Stachel D; Schrappe M; Alten J; Schrauder A; Schulz A; Lang P; Müller I; Albert MH; Willasch AM; Klingebiel TE; Peters C
J Clin Oncol; 2015 Apr; 33(11):1275-84. PubMed ID: 25605857
[TBL] [Abstract][Full Text] [Related]
20. Achieving Molecular Remission before Allogeneic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Impact on Relapse and Long-Term Outcome.
Lussana F; Intermesoli T; Gianni F; Boschini C; Masciulli A; Spinelli O; Oldani E; Tosi M; Grassi A; Parolini M; Audisio E; Cattaneo C; Raimondi R; Angelucci E; Cavattoni IM; Scattolin AM; Cortelezzi A; Mannelli F; Ciceri F; Mattei D; Borlenghi E; Terruzzi E; Romani C; Bassan R; Rambaldi A
Biol Blood Marrow Transplant; 2016 Nov; 22(11):1983-1987. PubMed ID: 27492792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
